Emerging Technologies 2018 Session Listing
The program is subject to change in the weeks leading up to the conference. Check back here for the latest schedule, or follow us on Twitter for real-time notice of updates to the program.
We plan to have a firm program available no later than February 5, 2018.
Session D2: Medical Imaging
Start Time: 09:00, Thursday, May 10
Chaired by Jan Iwanczyk, DxRay, Inc. (email@example.com) and Yi-Hwa Liu, Yale University (firstname.lastname@example.org)
- Chin-Tu Chen, University of Chicago
with C. Kao, L. Leoni, H. Zhang, S. Cheng, M. Bhuiyan, N. Chen, N. Eclov, H. Kim, J. George, B. Quigley, H. Tsai, A.
Kucharski, J. Souris, C. Pelizzari, R. Freifelder, I. Balyasnikova, L. Meng, P. La Riviere and L. Lo
Imaging-guided X-ray induced photodynamic therapy (XPDT) using novel nanoparticles
We have been developing a Molecular RadioNano-Theranostics Research Program, emphasizing on integrating nuclear medicine technology with nanotechnology to deliver precision medicine using novel molecular diagnostic imaging and image-guided molecular therapy approaches. We have successfully developed following key emerging technologies with a central theme on X-ray induced photodynamic therapy (XPDT): (1) multi-modality molecular imaging instrumentation in PET, SPECT, CT and optical imaging using novel semiconductor-based radiation detector technologies; (2) molecular radionano-theranostic chemistry integrating radioimmuno-technology and nanotechnology with target delivery considerations; (3) image reconstruction, processing and analysis using accurate physical modeling, novel algorithm designs, and fast computing techniques. We will illustrate our progresses by demonstrating the uses of x-ray nanoscintillators capable of generating significant amount of cytotoxic reactive oxygen species (ROS) under low-dose, low-energy x-ray activation in XPDT treatment of ovarian cancer. Our nanoplatform Y2O3:Eu@mSiO2 is used not only to generate singlet oxygen but to also deliver radiosensitizing and other therapeutic drugs. In animal experiments using ovarian cancer models, we are using several innovative imaging devices, designed and developed in our own laboratories, to monitor the luminescence and fluorescence signals for treatment planning and assessment, as well as for evaluation of the tumor progression and therapeutic effects after the XPDT treatment using SPECT and PET radiotracer imaging methods.
- Speaker to be Confirmed, MARS Research Group, New Zealand
MARS spectral CT: using CZT in a biomedical tool
- William Barber, DxRay, Inc. (email@example.com)
- Vesna Sossi, University of British Columbia (firstname.lastname@example.org)
- COFFEE BREAK
Support from our sponsors allows us to provide additional special events and networking opportunities during our conferences.